Alterity Therapeutics (ATHE) Net Shares Issued and Repurchased (2015 - 2025)

Alterity Therapeutics' Net Shares Issued and Repurchased history runs 11 years deep, the most recent figure standing at $185.5 million for Q4 2025.

• In Q4 2025, Net Shares Issued and Repurchased rose 26.9% year-over-year to $185.5 million; the TTM figure through Dec 2025 stood at $185.5 million (up 26.9% YoY), while the FY2025 annual figure was $168.4 million, up 14.51% from the prior year.
• Net Shares Issued and Repurchased for Q4 2025 stood at $185.5 million, up from $168.4 million in the prior quarter.
• The five-year high for Net Shares Issued and Repurchased was $185.5 million in Q4 2025, with the low at $2.1 million in Q2 2023.
• The 5-year median for Net Shares Issued and Repurchased is $149.1 million (2021), against an average of $124.6 million.
• The sharpest annual moves came in 2023 and 2025: Net Shares Issued and Repurchased slumped 98.6% in 2023, then soared 7446.46% in 2025.
• Alterity Therapeutics' Net Shares Issued and Repurchased stood at $155.8 million in 2021, then decreased by 9.81% to $140.5 million in 2022, then retreated by 0.39% to $139.9 million in 2023, then grew by 4.45% to $146.2 million in 2024, then rose by 26.9% to $185.5 million in 2025.
• Business Quant data shows ATHE's Net Shares Issued and Repurchased at $185.5 million in Q4 2025, $168.4 million in Q2 2025, and $146.2 million in Q4 2024.